Sunday, August 30, 2026

Crude Oil Bearish Momentum: 2.52% Down Since The Last Session

ViaNews Editorial Team

January 15, 2021

Crude Oil Bearish Momentum: 2.52% Down Since The Last Session

Crude Oil is currently on bearish momentum. At 14:03 EST on Friday, 15 January, Crude Oil is at $52.22 and 2.52% down since the last session's close.

Crude Oil Range

Crude Oil is 2.72% down from its last session low of $53.68 and 2.991% down from its last session high of $53.83.

Crude Oil is 2.99% down from its last three sessions higher value of $53.83 and is 0.97% down from its last three sessions lower value of $52.73.

Crude Oil is 2.99% down from its last seven sessions higher value of $53.83 and is 2.78% up from its last seven sessions lower value of $50.81.

Crude Oil is 2.99% down from its last month's higher value of $53.83 and is 13.08% up from its last month's lower value of $46.18.

Volatility

Crude Oil's last day, last week, and last month's average volatility was 1.66%, 0.53%, and 0.32%, respectively.

Crude Oil's last day, last week, and last month's high and low average amplitude percentage was 0.28%, 0.40%, and 1.01%, respectively.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com